A Phase I Study of RMC-5552 in People with Persistent Solid Tumors

Share

Full Title

A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors

Purpose

The purpose of this study is to find the highest dose of the investigational drug RMC-5552 that can be given safely in people with solid tumor cancers that continue to grow despite prior treatment. RMC-5552 blocks a protein called mTOR and may slow or stop cancer growth. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have an advanced malignant solid tumor that came back or continued to grow despite treatment.
  • Patients should recover from the serious side effects of previous therapies before receiving RMC-5552.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr.  Alison Schram at 646-888-5388.

Protocol

21-387

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Diseases